Literature DB >> 12694843

Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease.

Jason Chia-Hsien Cheng1, Jian Kuen Wu, Chao-Ming Huang, Hua-Shan Liu, David Y Huang, Stella Y Tsai, Skye Hongiun Cheng, James Jer-Min Jian, Andrew T Huang.   

Abstract

PURPOSE: This study compares the difference in dose-volume data between three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) for patients with hepatocellular carcinoma (HCC) and previously documented radiation-induced liver disease (RILD) after 3D-CRT.
MATERIALS AND METHODS: Between November 1993 and December 1999, 68 patients with HCC were treated with 3D-CRT at our institution. Twelve of them were diagnosed with RILD within 4 months of completion of 3D-CRT. RILD was defined as either anicteric elevation of alkaline phosphatase level of at least twofold and nonmalignant ascites, or elevated transaminases of at least fivefold the upper limit of normal or of pretreatment levels. Three-dimensional treatment planning using dose-volume histograms of normal liver was used to obtain the dose-volume data. These 12 patients with RILD were replanned with an IMRT planning system using the five-field (gantry angles 0 degrees, 72 degrees, 144 degrees, 216 degrees, and 288 degrees ) step-and-shoot technique to compare the dosimetric difference in targets and organs at risk between 3D-CRT and IMRT. Mean dose and normal tissue complication probability with literature-cited volume effect parameter of 0.32, curve steepness parameter of 0.15, and TD(50)(1) of 40 Gy, were used for the liver, whereas volume fraction at a given dose level was used for other critical structures. Paired Student t-test with 2-tailed p < 0.05 was used to assess the statistical difference between the two techniques.
RESULTS: With comparable target coverage between 3D-CRT and five-field step-and-shoot IMRT, IMRT was able to obtain a large dose reduction in the spinal cord (5.7% vs. 33.2%, p = 0.007), and achieved at least similar organ sparing for kidneys and stomach. IMRT had diverse dosimetric effect on liver, with significant reduction in normal tissue complication probability (23.7% vs. 36.6%, p = 0.009), but significant increase in mean dose (2924 cGy vs. 2504 cGy, p = 0.009), as compared with 3D-CRT.
CONCLUSIONS: IMRT is capable of preserving acceptable target coverage and improving or at least maintaining the nonhepatic organ sparing for patients with HCC and previously diagnosed RILD after 3D-CRT. The true impact of this technique on the liver remains unsettled and may depend on the exact volume effect of this organ.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694843     DOI: 10.1016/s0360-3016(03)00091-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Yasue Niwa; Masayuki Mima; Osamu Fujii; Ryohei Sasaki; Isamu Yamada; Yuichi Hori; Yoshio Hishikawa; Mitsuyuki Abe; Yonson Ku; Masao Murakami
Journal:  J Gastroenterol       Date:  2011-04-23       Impact factor: 7.527

2.  RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.

Authors:  J M Park; K Kim; E K Chie; C H Choi; S J Ye; S W Ha
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

3.  Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.

Authors:  Bertrand Janne d'Othée; Constantinos T Sofocleous; Nader Hanna; Robert J Lewandowski; Michael C Soulen; Jean-Nicolas Vauthey; Steven J Cohen; Alan P Venook; Matthew S Johnson; Andrew S Kennedy; Ravi Murthy; Jean-Francois Geschwind; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-02       Impact factor: 3.464

4.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 5.  Technical advances in external radiotherapy for hepatocellular carcinoma.

Authors:  Shin-Hyung Park; Jae-Chul Kim; Min Kyu Kang
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

6.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  De-Hua Wu; Li Liu; Long-Hua Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

7.  Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments.

Authors:  P-M Wang; W-C Hsu; N-N Chung; F-L Chang; A Fogliata; L Cozzi
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

8.  Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma.

Authors:  Hong In Yoon; Ik Jae Lee; Kwang-Hyub Han; Jinsil Seong
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-09       Impact factor: 4.553

9.  Helical tomotherapy for single and multiple liver tumours.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Fu-Min Fang; Te-Jen Su; Stephen W Leung; Hsuan-Chih Hsu
Journal:  Radiat Oncol       Date:  2010-06-24       Impact factor: 3.481

10.  Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma.

Authors:  Chen-Hsi Hsieh; Chia-Yuan Liu; Pei-Wei Shueng; Ngot-Swan Chong; Chih-Jen Chen; Ming-Jen Chen; Ching-Chung Lin; Tsang-En Wang; Shee-Chan Lin; Hung-Chi Tai; Hui-Ju Tien; Kuo-Hsin Chen; Li-Ying Wang; Yen-Ping Hsieh; David Y C Huang; Yu-Jen Chen
Journal:  Radiat Oncol       Date:  2010-05-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.